Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Core Scientific (CORZ) Gains from Investment Securities: 2021-2025

Historic Gains from Investment Securities for Core Scientific (CORZ) over the last 5 years, with Sep 2025 value amounting to -$2.9 million.

  • Core Scientific's Gains from Investment Securities fell 476.23% to -$2.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.4 million, marking a year-over-year increase of 63.58%. This contributed to the annual value of $6.0 million for FY2024, which is 65.06% up from last year.
  • Per Core Scientific's latest filing, its Gains from Investment Securities stood at -$2.9 million for Q3 2025, which was up 29.60% from -$4.2 million recorded in Q2 2025.
  • Core Scientific's Gains from Investment Securities' 5-year high stood at $93.8 million during Q4 2021, with a 5-year trough of -$22.2 million in Q2 2022.
  • Moreover, its 3-year median value for Gains from Investment Securities was -$174,000 (2023), whereas its average is -$489,727.
  • In the last 5 years, Core Scientific's Gains from Investment Securities slumped by 130,423.53% in 2022 and then spiked by 254.02% in 2024.
  • Quarterly analysis of 5 years shows Core Scientific's Gains from Investment Securities stood at $93.8 million in 2021, then slumped by 32.51% to $63.3 million in 2022, then plummeted by 99.61% to $247,000 in 2023, then skyrocketed by 187.45% to $710,000 in 2024, then tumbled by 476.23% to -$2.9 million in 2025.
  • Its Gains from Investment Securities stands at -$2.9 million for Q3 2025, versus -$4.2 million for Q2 2025 and $5.0 million for Q1 2025.